Clinical Trial Initiations, Conferences Participations, Strategic Collaborations, and Presentation of New Pre-Clinical Data -

      Clinical Trial Initiations, Conferences Participations, Strategic
Collaborations, and Presentation of New Pre-Clinical Data - Research Report on
            Biogen Idec, BioMarin, Medivation, Cytori, and Alnylam

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 8, 2013

NEW YORK, November 8, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Biogen
Idec Inc. (NASDAQ: BIIB), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN),
Medivation, Inc. (NASDAQ: MDVN), Cytori Therapeutics, Inc. (NASDAQ: CYTX), and
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Biogen Idec Inc. Research Report

On November 5, 2013, Biogen Idec Inc. (Biogen Idec) announced that it is
scheduled to present at the Credit Suisse Global Healthcare Conference on
Tuesday, November 12, 2013, at 8:30 a.m. MST / 10:30 a.m. ET. The Company
informed that a live webcast of the presentation can be accessed by interested
parties through the Company's website. The Full Research Report on Biogen Idec
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/b95b_BIIB]

--

BioMarin Pharmaceutical Inc. Research Report

On October 31, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that it
has initiated its Phase 3 Trial for BMN 673 for the treatment of metastatic
germline BRCA muted breast cancer. BioMarin informed that it has dosed the
first patient in the Phase 3 program to evaluate its poly ADP-ribose
polymerase (PARP) inhibitor, BMN 673. According to the Company, the Phase 3
study is an open-label, randomized, parallel, two-arm, multi-center study of
BMN 673, against physician's choice in approximately 430 germline BRCA
mutation patients with locally advanced and/or metastatic breast cancer, who
have received no more than two prior chemotherapy regimens for metastatic
disease. "We are eager to fully enroll this important trial for breast cancer
patients with hereditary breast cancer to better understand the role of BMN
673 in this defined population," said Hank Fuchs, M.D., Chief Medical Officer
of BioMarin. "We are looking forward to gaining a better understanding of the
safety and efficacy of our compound." The Full Research Report on BioMarin
Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/9b6c_BMRN]

--

Medivation, Inc. Research Report 

On October 30, 2013, Medivation, Inc. (Medivation) announced its scheduled
participation at two upcoming investor conferences in November 2013. According
to the Company, its M.D, President and CEO, David, Hung will represent
Medivation at the Credit Suisse Healthcare Conference on Wednesday, November
13, 2013, at 1:30 p.m. at the Phoenician Hotel in Scottsdale, Arizona; and at
the Jefferies 2013 London Healthcare Conference on Wednesday November 20,
2013, at 2:20 p.m. at the Waldorf Hilton in London. The Company informed that
interested individuals may access the live audio webcast of the presentations
at the Company's website. The Full Research Report on Medivation, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4277_MDVN]

--

Cytori Therapeutics, Inc. Research Report

On November 4, 2013, Cytori Therapeutics Inc. (Cytori) and Lorem Vascular
jointly announced its strategic collaboration to commercialize Cytori Cell
Therapy for the cardiovascular, renal and diabetes markets in China, Hong
Kong, Malaysia, Singapore and Australia. According to the Company, under the
terms of agreement, Lorem Vascular will pay $531 million in license fees,
opening product purchase commitments and Cytori equity purchases. "Through
this agreement with Lorem Vascular, we have secured a committed partner to
bring Cytori Cell Therapy to patients in countries where we have recently
received, or are in the process of achieving, regulatory approval," said
Christopher J. Calhoun, CEO of Cytori. "With the Celution® System now approved
and available in more than 40 countries, we are uniquely positioned to expand
our cell therapy brand by being first-to-market with cell therapy products in
new geographies around the world. Lorem Vascular brings to Cytori the required
resources, market knowledge, dedication and focus to commercialize this
innovative treatment and pioneer the introduction of cell therapy products for
patients with the most serious conditions." The Full Research Report on Cytori
Therapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/e1ae_CYTX]

--

Alnylam Pharmaceuticals, Inc. Research Report 

On November 2, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced its
presentation of a new pre-clinical data with ALN-AAT, an RNAi therapeutic
targeting alpha-1 antitrypsin (AAT) in development for the treatment of liver
disease associated with AAT deficiency. According to the Company, Alnylam
scientists and collaborators presented new results in a transgenic mouse model
of Z-AAT protein over-expression showing that subcutaneous administration of a
GalNAc-siRNA targeting AAT led to rapid, potent, dose-dependent, and durable
knockdown of AAT of greater than 90%, as well as a significant reduction in
fibrosis and the incidence of liver tumors. Rachel Meyers, Ph.D., Vice
President of Research and RNAi Lead Development at Alnylam said, "Our new
pre-clinical data with a GalNAc-siRNA conjugate against AAT demonstrate rapid,
potent, dose-dependent, and durable knockdown of AAT to greater than 90%
resulting in a significant reduction of liver fibrosis and tumor formation. If
these results extend in clinical studies, we believe that ALN-AAT could become
an important treatment option for the management of disease in people with AAT
deficiency." The Full Research Report on Alnylam Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/5b29_ALNY]

---

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)